Numerous amphiphilic cationic drugs cause generalized phospholipidosis in animals; one of these drugs is the Sandoz compound 200-125, a psychotropic agent. During a 6-month toxicity study in Charles River CD rats, a dramatic increase in foamy macrophages was seen in the lungs. A follow-up experiment was done to study the pathologic basis of these changes including a reversibility phase. Generalized phospholipidosis was induced after 4 weeks of 500 mg/kg/ day of 200-125 by gavage. Characteristic pulmonary lesions consisted of extensive accumulations of large pale foamy macrophages as well as granular eosinophilic extracellular material. lipid analyses of lungs showed marked increases in phospholipids (144%) and cholesterol esters (1 10%) in rats treated with 200-125. Drug metabolism studies employing "C-labeled 200-125 showed an affinity for the drug to concentrate in the lungs and lymphoreticular system (spleen, lymph nodes) a s well as in the adrenals, liver, and kidney. Reversibility of the phospholipidosis was nearly complete 4 weeks after drug withdrawal. The tissue changes were characterized by transmission and scanning electron microscopy. The potential pulmonary toxicity in humans with the amphiphiles is discussed.
INTRODUCTION
..is an antipsychotic drug developed with a specific selectivity for dopamine D-1 receptors and which has limited adverse extrapyramidal effects. The molecular structure ( Fig. 1) of is that of an amphiphilic base with a halogenated hydrophobic ring system and a short hydrophilic side chain. Thus it is similar in structure to many other amphiphilic cationic compounds which induce generalized phospholipidosis in animals (8, 11, [13] [14] [15] 25) . The purpose of the described experiments was initially to conduct a 6-month safety 'evaluation study and then to evaluate the generalized phospholipidosis induced by compound 200-125 in the rat. This report will focus on Institutional Animal Care and Use Committee.
Experiment I. In the first experiment, 15 young adult Charles River CD (Sprague Dawley derived) rats, approximately 5 weeks old, of each sex per dose group were given by gavage daily for 26 weeks. The control animals received 10 ml/kg of water while the 200-125 groups received 28, 112, or 240 mg/ kg in water (10 ml/kg], respectively. An additional 58 animals were placed on study for drug metabolism studies. Daily observations, ophthalmoscopic examinations, and body weights (twice weekly through drug week 13 and weekly thereafter) were taken on all animals. Routine hematology, clinical chemistry, and urinalysis determinations were performed in drug weeks 4,8,12,18, and 25. All animals were fasted overnight (about 18 hr) prior to the collection of blood for the hematology or clinical chemistry analyses. The hematologic parameters evaluated included counts of the erythrocytes, nucleated erythrocytes, reticulocytes, platelets, hematocrit, hemoglobin, MCH, MCHC, MCV plus differential, and total leukocytes. For the clinical chemistries, glucose, BUN, ALT (SGPT), AST (SGOT), alkaline phosphatase, total serum proteins, sodium, potassium, and chloride were determined. Urinalyses included specific gravity and pH, qualitative tests for proteins, ketones, glucose, occult blood, and microscopic evaluation of the centrifugal sediment. Statistical analyses were performed ' by using a one-way analysis of variance followed by a Duncan's Multiple Range Test. Statistical significance was established as p L 0.05.
A complete necropsy was performed on each animal. At the end of the dosing period during week 27, all surviving animals were necropsied and approximately 50 tissues were examined histopathologically from each rat in the study. Terminal body weights and seven organ weights were taken from each killed rat.
A parallel drug metabolism study was conducted utilizing 58 animals that had been maintained and treated identically as the 26- week toxicology animals (Experiment I). Single low (28 mg/kg) or high (264 mg/kg] doses of ''C-labeled 200-125 (24) (25) (26) (27) (28) pCi/kg) were administered to animals that had received water only by gavage for approximately 24 weeks. At selected intervals following the radioactive dose, three animals in each dose group were killed and the blood, tissues, and organs removed and analyzed for total radioactivity. The chronically dosed animals received by gavage with the toxicology animals between 25 and 26 weeks. The multiple dosed animals assigned to the drug metabolism studies then received a final dose of either 28 or 240 mg/kg of 14C-labeled 200-125. Serial blood samples, feces, and urine were collected at selected intervals for the 96 hr following the radiolabeled dose. At 96 hr the rats were killed and the blood, 'tissues, and organs analyzed for radioactivity; results were compared with those obtained after a single dose.
For diagnostic transmission electron microscopy, pieces of lung initially fixed in 10% formalin, were minced and washed in 0.1 M cacodylate buffer to remove the formalin from the tissue. Postfixation included 2.5% cacodylate-buffered glutaraldehyde and final fixation in 1 % cacodylate-buffered osmium tetroxide. The samples were dehydrated through an upgraded ethanol series followed by eqbedment in Epon 812. Thin sections (600 A] were cut with diamond knives, double-stained with uranyl acetate and lead citrate, and examined in a Zeiss EM942 electron microscope.
Experimen t II. A follow-up experiment employed 40 young adult male Charles River CD rats, approximately 5 weeks old, that were randomly assigned to four groups of 10 animals each. Two groups were used to study the effects of 200-125 by gavage at 500 mg/ kg/day and its reversibility; a third group was given the reference compound Tamoxifen (130 mg/kg daily). Tamoxifen, an antiestrogenic agent, was given as a reference compound since it has been shown to be a potent inducer of generalized phospholipidosis in rats (11) . The fourth group served as controls and received only water. The drug phase of the study ran for 4 weeks followed by a 4-week reversibility phase. The dose of was lowered to 250 mg/kg/day on day 8 and the dose level of Tamoxifen was lowered to 100 mg/kg/day on day 9 to reduce mortality. Daily observations and body weights were taken during the first 4 weeks of the study; once daily observations were continued during the recovery phase. Scheduled necropsies were performed on days 29 and 57. A complete necropsy was performed on all animals; a limited tissue collection comprising 10 tissues plus all gross lesions was done. Wet weights of the lungs and livers were also determined.
Light microscopy was performed on hematoxylin and eosin-stained sections of lung, liver, kidney, lymph node, and all gross lesions. Special stains for phospholipids (otan, acid liematin, and gold-hydroxamic acid) were done on lung specimens. At death, pieces of lung, adrenal, and mesenteric lymph node were minced in 2.5% cacodylatebuffered glutaraldehyde (pH 7.4), washed in cacodylate buffer, and postfixed in 1% cacodylate-buffered osmium tetroxide. Liver samples were fixed in 1.3% sym-collidinebuffered osmium tetroxide (4°C). The samples were dehydrated through an upgraded ethanol series and embedded in Epon 812. Ultrathin sections were double stained with uranyl acetate and lead citrate and examined with a Zeiss EM9-S2 eIectron microscope.
Samples of lung from control and 200-125-treated rats were processed and surveyed by scanning electron microscopy. Samples were fixed overnight in paraformaldehyde (2%), glutaraldehyde (2.5%) fixative. The tissue was then washed in cacodylate buffer prior to postfixation for 2 hr in 1% osmium tetroxide. The lung samples were critically point dried from ethanol through carbon. dioxide and coated with approximately 125 A of pure gold for secondary emissive scanning electron microscopy. Survey and photography were performed with an Amray 1600 electron microscope.
Acid phosphatase activity in lung and liver specimens fixed in 2.5% glutaraldehyde was demonstrated ultrastructurally by the method of Shio (24) . Then'30-40 p thick sections were incubated at 37°C for 2 hr in a modified Gomori medium containing 40 mM Tris-maleate buffer, pH 5.0, 2.4 mM lead nitrate, and 11.5 mM @-glycerophosphate as substrate. Control sections were incubated without substrate. After incubation, sections were washed in 0.1 M cacodylate buffer and further processed for transmission electron microscopy. Thin sections were viewed unstained.
The left lobe of the lung from each rat surviving until sacrifice was frozen until extracted for biochemical analyses. Lung total lipids were extracted according to the method of Folch (3). Analyses of the different lipids were performed using aliquots of the Folch extracts. For triglycerides, 10 ml of the extracts were evaporated to dryness under nitrogen, redissolved in 10 ml of isopropanol, treated, and analyzed according to AutoAnalyzer method N78 based on the fluorometric method of Kessler and Lederer (7). Total and free lung cholesterol were analyzed on the same isopropanol extract using the enzymatic AutoAnalyzer I1 method of Lie (9). Esterified cholesterol levels were calculated from the difference between total and free cholesterol. For phospholipids, 2 ml of the Folch extract were evaporated to dryness under nitrogen, redissolved in 5 ml of N NaOH and assayed according to the AutoAnalyzer method of Whitley and Alburn (28) . Statistical analysis was done with the use of Student's t test.
RESULTS
The administration of 200-125 for 26 weeks produced toxicologic effects that were of only mild to moderate severity incIuding a dosedependent decrease in locomotor activity, body weight gain, and yellow-brown-stained fur in the urogenital region. No drug-related mortality was observed during the experiment. The decrease in locomotor activity was greatest in the high dose groups; where it was generally mild in degree. The severity of this sign decreased during the study until the 5th week of drug administration when it was observed only occasionally thereafter. The stained fur was observed in both the mid and high dose females but only in the high dose males. No other clinical signs were produced by the drug.
A decrease in body weight gain was observed only in high dose animals of both sexes. This effect was first noted during the 1st week of drug administration and resulted in an approximate 10% decrease in .body weight during the 2nd week of the study. At the termination of the %-week study the reduced body weight gain had produced an approximate 19 and 15% decrease in actual body weight for the male and female high dose animals. , Detailed hematologic, clinical chemistry, and urinalysis examinations reveaIed only several mild drug-related effects. A mild increase in total leukocytes and segmented neutrophils was observed for the high dose male and female rats ( Table I) . These increases were consistently observed during the study and approximated increases ranging from 57-140% for the males and from 26-151% for the females, as compared to controls. No other drug-related alterations were observed for the hematologic parameters that were examined.
Mild drug-related effects on several clinical chemistry parameters were observed including decreases for blood glucose and chloride and increases for blood urea nitrogen (BUN), alkaline phosphatase, total serum protein, and sodium. The data are not presented but the effects on glucose and BUN at the high dose were moderate, generally representing changes from 20-40%. Total protein, sodium, and chloride were altered to a lesser extent at the high dose with the alteration compared to controls being approximately 4-10%. No drug-related effect on serum levels of potassium was observed.
A mild drug-related increase in alkaline phosphatase levels were observed in both sexes at the high dose. These increases were approximately 30% in the 4th week and by the 26th week were increased by a two to three factor over the control level. There were no drug-related alterations of the serum transaminases (ALT and AST). No significant changes in any of the urinalysis parameters were noted.
At necropsy, patchy yellow discolored areas were noted in the pleura of the lungs with extension into the pulmonary parenchyma in the mid and high dose. In addition, the liver and thyroid were darker than usual. Liver weights were increased in both mid and high dose rats of both sexes.
A tremendous proliferation of alveolar macrophages and an accumulation of fine granular, eosinophilic debris filling the pulmonary alveolar spaces were observed by light microscopy in most mid and high dose rats. This lesion corresponded to the patchy yellow areas in the lungs seen grossly. In addition, large, pale pigmented, histiocytes were found in the paracortical areas of the spleen, thymus, and various lymph nodes. No other significant microscopic lesions relating to generalized phospholipidosis were seen in the other tissues examined. Pigment accumulation was seen in lymphocytes and thyroid follicular cells as well as in the reticuloendothelial system. The pigment was morphologically compatible with lipofuscin. Diagnostic electron microscopy of lung samples from high dose rats revealed -lesions suggestive of drug-induced phospholipidosis (10) . Abnormal lamellated or crystalloid inclusion bodies were found either free in the pulmonary alveoli or within type I and type I1 pneumocytes as well as in alveolar macrophages, endothelial cells, and neutrophils. In particular, the numbers of alveolar macrophages were greatly increased and appeared stuffed with membrane-bound inclusions.
The single dose metabolism studies showed an affinity for the drug to concentrate in the lungs, spleen, lymph nodes, adrenal, thyroid, and pituitary glands (Fig. 2) . Additionally, the concentrations in the liver and kidneys were high which would be expected since these are the primary organs of xenobiotic metabolism and excretion. A dose-dependent proportionality was not observed for the dosenormalized tissue concentrations. Concentrations of radioactivity were 5 to 10 times higher in most tissues and 30 times greater in the lungs after a single high drug dose as compared with a low dose. These 24-hr radiolabel concentrations would predict substantial accumulation after chronic administration. This was supported by the relatively higher concentration -of radioactivity observed at 96 hr in the lungs, spleen, adrenals, liver, and kidneys of the rats (Group IV) dosed 240 mg/kg/day when compared to the Group I1 rats receiving 28 mg/kg/day (Fig. 3) . A greater accumulation was also observed in the females than in the males of the high dose group.
A follow up experiment was designed to further evaluate the generalized phospholipidosis. Compound was given at high doses to study the induction and reversibility of the phospholipidosis phenomenon. Tamoxifen was given as a reference compound (1 1). Drug-induced mortality was produced in 5 of 10 animals given Tamoxifen and 5 of 20 animals given 200-125 prior to death. In-life observations and body weight changes were similar to those seen in the initial 26-week toxicity study. At necropsy, pale yellow to brown patchy areas on the pleural surface and extending into the parenchyma in the lungs were seen in 6 of 10 rats treated with 200-125,2 of 10 treated with 200-125 reversibility, and 2 of 10 rats treated with Tamoxifen.
Actual and relative lung weights were increased in 200-125-treated rats whereas only the relative lung weight was increased for the Tamoxifen groups. Relative liver weights were increased for both compounds. Reversibility of these effects of 200-125 occurred as both liver and lung weights returned to control levels (Table 11) .
Microscopically, foamy macrophage aggregates in the alveolar spaces of the lung were evident in 9 of 10 rats treated with (Fig. 4) and 9 of 10 rats treated with Tamoxifen. The lesion consisted of extensive accumulations of large pale foamy cells with some granular eosinophilic extracellular material present. The areas were multifocal or diffuse and moderately to strongly positive for the special stains for phospholipids (otan, acid hematin). These areas were identical with those seen in the previous 6-month study. Significant changes were not seen in the other tissues examined. Reversibility of these lesions after 4 weeks off drug was virtually complete as seen by light microscopy with only a few foam cells and no extracellular material present in alveoli. These sparse remnant lesions correlated with the few gross lesions present in 2 of 10 reversibility rats.
By transmission and scanning electron microscopy, ultrastructural features of lung samples from control animals were not remarkable (Figs. 5 and 8a) (1, 19, 27) . The inner surface of the alveolus was lined with two cell types: membranous pneumocytes (Type I cells) and granular pneumocytes (Type I1 cells). Alveolar macrophages were very occasionally seen in the alveolar sacs. Compound 200-125-treated rats had a massive increase in alveolar macrophages as well as abnormal lamellar or lattice-like membrane profiles in the alveolar lumina and within alveolar macrophages (Fig. 6) . Heterogeneous dense and/or lamellar bodies also were observed in Type I and Type I1 pneumocytes, pulmonary capillary endothelial cells, and neutrophils.
The alveolar lumina contained secretions seen as either densely packed multilaminated membrane (lamellar) bodies or tubular lattices (Fig. 6, inset) . These configurations are characteristic for phospholipids. in an aqueous environment (26) . In some areas the alveolar sacs and macrophages were 'completely filled with this material. In alveolar macrophages from control rats, some lysosomes or pliagolysosomes were seen. In alveolar macrophages from 200-125-treated rats, abundant lamellar, multilaminated, or heterogeneous dense bodies were present (Fig. 7) .
In Type I cells from 200-125-treated animals, distinct heterogeneous dense bodies and lamellar bodies were. seen within the attenuated cytoplasm. These tightly packed membranes display$d a periodicity of approximately 50-60 A (Fig. 6) and were observed only in the 200-125-treated animals.
Within the Type I1 pneumocytes, loosely packed concentric membrane inclusions were seen. Also noted in Type I1 cells was an increase in various stages of lysosomes with secondary lysosomes apparently transforming into the concentric membrane inclusions. The accumulation of lamellar bodies was also noted in a few neutrophils within the alveolar air spaces.
By scanning electron microscopy, the surfaces of the alveolar spaces from 200-125-treated rats were covered by many cells (primarily alveolar macrophages) and filled with fibrous or loosely packed extracellular material (Fig. 8B) . Alveolar pores were not recognizable and the air spaces were almost completely occluded in affected areas.
The cessation of 200-125 treatment for the 4-week recovery period resulted in an almost complete reversal of the lesions. Lung samples examined from animals in the 200-125 reversibility portion of this experiment were comparable to control rats in the areas examined. The alveolar lumina were clear of lamellar or lattice-like membrane profiles and contained only a few alveolar macrophages. Most types. Also the absence of membraneoy inclusions in Type I and I1 pneumocytes and alveolar macrophages was noted. The cytosomes of Type I1 pneumocytes were comparable to those of control Type I1 cells.
The presence of acid phosphatase activity was used to determine the relationship of lysosomes to the inclusions seen in 200-125-treated rats. In selected instances, lung samples prepared with substrate showed a lead deposit at the periphery of the vacuoles containing the inclusion bodies, thus providing evidence for the localization of the inclusions within lysosomal vacuoles.
Distinct morphologic changes were also noted using TEM in various other tissues from 200-125-treated rats. The ultrastructurd examination of liver revealed a n increase in the smooth endoplasmic reticulum (SER) and secondary lysosomes. Increased lysosome numbers were also noted in hepatic Kupffer cells. Characteristic multilamellated bodies were seen in lymphocytes. Lymphocytes from the mesenteric lymph node had a marked increase in lysosome numbers and lamellar inclusion bodies similar to those noted in alveolar Type I cells (Fig. 9A) . Similar findings were also noted within macrophages in the mesenteric lymph nodes examined. Also noted was an increase in lysosome numbers in the endothelial cells of capillaries surveyed in the lymph nodes. Distinct morphologic change was also seen in the epithelial cells of the adrenal cortex of rats administered (Fig. 9B) . These changes included an increase in lysosome number and the observation of lamellar bodies as previously described in the lung, liver, and mesenteric lymph nodes.
Lipid analyses of lungs from Tamoxifentreated rats showed marked (77%) increases in the levels of phospholipids, mild increases in cholesterol esters, and minimal increases in total cholesterol, free cholesterol, and triglyceride levels (Table 111) . Qualitatively similar but greater lipid accumulations were encountered in lungs of rats treated with 200-125. Marked increases were observed in phospholipids (144%) and cholesterol esters (110%) in lungs of rats treated with 200-125. Slight to moderate increases were also recorded in total and free cholesterol levels of Iungs of 200-125-treated rats. Removal of for 4 weeks allowed the lung lipid levels to return to control levels. Lung phospholipids were only slightly elevated (16%) and triglycerides were slightly reduced (26%) in lungs of rats at the end of the reversibility phase after 200-125 treatment.
DISCUSSION
The data presented in this communication indicate that can be added to the large list of compounds which can indude a secondary lysosomal storage disorder. It appears that this phenomenon observed in rats treated with fulfilled all of the criteria for this type of lysosomal dysfunction as set forth by Lullman-Rauch (14) . Namely, these include the presence of generalized membrane-bound, acid phosphatase-positive cytoplasmic inclusions with a myelinoid or crystalline-like ultrastructure; the accumulation of increased amounts of polar lipids in the affected cells or tissues; the accumulation of the inducing drug together with the lipids; and the reversibility of the alterations after discontinuance of drug treatment. The ability of to induce phospholipidosis is not surprising when it is recognized that the related neuroleptics thioridazine and clozapine have been shown to induce some of these effects in limited studies of ultrastructural changes in lymph nodes and other tissues of experimental animals (4, 12).
Despite the ability of 200-125 to induce quite marked phospholipidosis in the lungs, thymus, spleen, and lymph nodes, the chemical produced relatively mild general toxicologic effects. M M e phospholipidosis was observed at 112 (mid dose) and 240 mg/kg (high dose), the body weight gain at only the high dose was significantly reduced. Detailed'hema tologic, clinical chemistry, and urinalysis revealed several biologically minor effects that were induced by the drug. The most interesting effects were the increases in segmented neutrophils and alkaline phosphatase. It is possible that this increase in circulating segmented neutrophils is in response to the massive influx of macrophages and polymorhonuclear leukocytes into the lungs and other areas of phospholipid accumulation. Although the increase in alkaline phosphatase would have suggested hepatotoxicity, no evidence of necrosis, choleostasis, or accumulation of phospholipid was observed in the liver. The precise mechanism by which cationic amphiphilic drugs induce a secondary lysosoma1 storage disease is still uncertain. Two mechanisms appear to be operative which are not necessarily mutually exclusive. Lullman et a1 have shown that the amphiphilic cationic drugs penetrate lysosomes where they become protonized and trapped in the acid milieu (10). Evidence from NMR studies indicates that the compounds form tightly bound complexes with phospholipid membranes which have increased resistance to degradation by lysosomal enzymes (22) . Recent evidence from tissue culture studies of liver and kidney cells indicates that these drugs inhibit lysosomal phospholipases A and C; this inhibition may be direct or indirect by increasing lysosomal alkalinity (5). Accumulation of lipids can then occur through a sustained flow of polar lipids from the cytosol into the lysosome taken together with the amphiphilic drug and result in the reduced ability for the complex to be enzymatically degraded. The result is the accumulation and persistence of phospholipid-rich multilaminated bodies in the lysosomes 'of affected cells. Among the most dramatically affected cells are those which are involved in the catabolism of excess biomembranes such as pulmonary alveolar macrophages, retinal pigment epithelium, Sertoli cells, and splenic phagocytes (14) .
Substantial accumulation of drug-related material occurred in the tissues which had morphologic evidence of phospholipidosis. Tissue and organ concentrations after a single dose of radiolabeled drug were substantially higher in rats'that had received chronic doses of 200-125 as compared with naive rats. This increased accumulation of radioactivity in the lungs and lymphoreticular system was much greater in the high dose group. There was also a significant increase in the tissue Ievels of female rats when compared to male rats of the same dose group. These high tissue levels are consistent with the longer terminal half-lives of radioactivity following chronic dosing hr) as compared to those following a single dose (43-47 hr) .
Biochemical analysis (Table 111) indicated that predominantly phospholipids accumulated in lungs of Tamoxifen-and 200-125-treated rats. Microscopically, lipids accumulated in lungs of rats in the form of multilaminated extracellular forms as well as in the lysosomes of alveolar macrophages and other cells in animals treated with the amphiphilic cationic compound 200-125. While phospholipids were the major lipid accumulated, accounting for over 90% of the lipid increase, cholesterol esters were also significantly increased. This is consistent with previous studies with chlorphentermine and other amphiphilic drugs (6, 20, 21) . Reversibility of the lipidosis in 200-125-treated rats was demonstrated since 4 weeks after drug withdrawal the lung lipids as well as pulmonary histopathology were nearly normalized.
During preclinical safety assessment studies using routine stains, lesions of generalized drug-induced phospholipidosis will be most readily recognized in the lungs but also may be present in circulating lymphocytes. Both the massive accumulations of foamy alveolar macrophages as well as abundant extracellular material in alveoli are distinctive characteristics of the condition. Among the most important functions of the alveolar macrophage is the phagocytosis and metabolism of surplus surfactant, which consists primarily of phospholipids and is continually secreted by Type I1 pneumocytes. Thus the pulmonary alveolar macrophage, which participates in the high phospholipid turnover which takes place under normal conditions, is profoundly affected under the influence of cationic amphiphilic drugs. The macrophages proliferate, become hypertrophic, and have greatly increased total phospholipid levels (50-100 x normal) (17,181. Eventually it is probable that necrosis occurs in some cells which contributes to the extracellular membrane material present in the alveolar spaces in advanced cases.
Toxicologists and other scientists involved in safety evaluation should be aware that cationic arnphiphilic drugs can induce adverse clinical reactions in humans. Reports from Japan first indicated that 4,4'-diethylaminoethoxyhexestrol, a coronary vasodilator, could induce a generalized phospholipidosis in man (23) . Since that time, patients treated with chloroquine and perhexiline have shown serious adverse side effects rela ted to induced phospholipidosis, namely ocular toxicity and peripheral neuropathies (14) . More recently,, the pulmonary toxicity associated with amiodarone administration has been demonstrated to be directly related to phospholipidosis in some cases (2, 16) .
The development of compound 200-125 as a new drug was not hindered because of the drug-induced phospholipidosis observed in the rat. The effect was not seen in our studies in the dog. Eventually the compound was dropped from further clinical development because of potential hepatotoxicity indicated by an unacceptable incidence of liver enzyme elevations. However there are a number of compounds on the market today which can induce generalized phospholipidosis in rodents under specific experimental conditions. The potential for cationic amphiphilic drugs to produce adverse side effects in man should be recognized and assessed as part of the overall safety evaluation. Special mechanistic studies will often be needed to make the diagnosis of drug-induced generalized phospholipidosis. Certainly the recognition of "myeloid bodies" in various tissues by TEM does not confirm the diagnosis as these can be seen in many conditions and may even be produced by inadequate fixation of tissues.
Scientists working in the field of drug safety evaluation need to be aware of the potential problem in man with amphiphilic cationic drugs and use a variety of techniques to obtain the data necessary to confirm the presence of generalized phospholipidosis.
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